LINC02216

Across TCGA pan-cancer cohorts, LINC02216 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of LINC02216’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where LINC02216 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02216 is over-expressed in tumor.

BLCA, BRCA, and KIRC are the cancer types where LINC02216 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC02216 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	+0.045	.012	3	view →
BRCA	All	II,III,IV	+0.044	.030	2	view →
KIRC	All	II,III,IV	+0.014	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

LINC02216–BLCA

Open the BLCA breakdown →